Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their ...

LONDON, GREATER LONDON, UNITED KINGDOM, January 22, 2025 /EINPresswire / -- What has been the historic growth trend in the abrysvo or arexvy global market and what is expected in the coming years?

0.93-4.40]) and Arexvy (7 excess cases per million doses; incidence rate ratio, 2.46 [95% CI, 1.19-5.08]). Results of this study, coupled with clinical trial data and reports to the Vaccine ...

The steep decline in Arexvy's turnover from £1.2 billion (around $1.5 billion) in 2023 to £590 million last year, follows the decision in the US to recommend RSV vaccines only for people aged 75 ...

Wednesday, GSK Plc (NYSE:GSK) reported fourth-quarter sales of $10.40 billion (8.12 billion Sterling Pounds), up 1% year-over-year ... by lower demand for Arexvy related to a more limited ACIP ...

Specialty medicines, which grew 19% in 2024, remain a key focus, with oncology sales nearly doubling to over £1.4 billion ... reflecting pressures on Arexvy and Shingrix in the U.S. However ...

Get Instant Summarized Text (Gist) The FDA has mandated safety labeling changes for the RSV vaccines Abrysvo and Arexvy to include warnings about the risk of Guillain-Barré syndrome (GBS ...

Arexvy has been approved for the prevention of lower respiratory tract disease caused by RSV in all individuals 60 years of age and older and for those aged 50 to 59 years at increased risk.

Vaccine sales fell 14% to £2.21B, with Arexvy sales down 70% ... each impacting full year growth by 1 percentage point. Shingrix sales reached 848 million pounds, down 7% (-4% at constant ...

GSK reported a similar state of affairs Wednesday. Sales of its RSV vaccine Arexvy declined 69% year over year due to lower demand “related to a more limited recommendation ... for individuals ...

So if you do that, the end of 2024, we had about a 58% market share. So about 4.1 doses out of 7 million were with Arexvy. I think we're happy with that. The key thing is to preserve value and ...

Concerns about GBS arose during the review of safety data from clinical trials prior to the approval of Abrysvo (manufactured by Pfizer) and Arexvy (manufactured ... window of 1-42 days after ...